-

Sotera Health Company (SHC) Investigation: Robbins LLP is Investigating the Officers and Directors of Sotera Health Company

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating the Sotera Health Company (NASDAQ: SHC) to determine whether certain Sotera officers and directors violated securities laws and breached fiduciary duties to shareholders in connection with the Company's public offerings and other statements made by the Company. Sotera provides sterilization and lab testing and advisory services to the medical device and pharmaceutical industries.

If you would like more information about our investigation of Sotera Health Company's misconduct submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Sotera Health Company's (SHC) EtO Processing Emitted Massive Toxins and Caused Cancer in People Living in the Communities Near its Facilities

According to the class action complaint filed against Sotera, the Company’s sterilization services relies on Ethylene Oxide (“EtO”) processing, which emits toxic fumes that must be filtered before being released into the air. In December 2016, the EPA reclassified EtO as a chemical known to be carcinogenic to humans and increased its estimate of EtO’s cancer potency by a multiple of thirty.

Sotera, through its Sterigenics business, conducts or has conducted EtO processing at facilities located in Illinois, California, Georgia, and New Mexico. In August 2018, the EPA reported that people living in communities near Sterigenics’ facilities in Illinois, Georgia, and New Mexico had among the highest cancer rates in the country. That same month, the U.S. Department of Health and Human Services released a report documenting the public health impacts of Sterigenics’ emissions on the area surrounding its Illinois facility and revealed the staggering and disproportionate risks of cancer in that area.

Beginning in September 2018, cancer-stricken plaintiffs filed a surge of lawsuits in Illinois against Sotera alleging that EtO emissions from the Company’s sterilization facility had caused their cancer. On September 30, 2019, Sotera announced the closure of its Illinois facility. Beginning in August 2020, cancer-stricken plaintiffs living in proximity to a Sterigenics facility in Georgia filed lawsuits similar to those filed in Illinois.

Sotera conducted its initial public offering on November 20, 2020 and its second public offering on March 18, 2021. The Offering Materials included numerous materially false and misleading representations concerning its emissions control systems and exposure to liability from lawsuits for the Company’s failure to limit harmful EtO emissions. The Company represented that it had “a proactive [environmental, health and safety] program and a culture of safety and quality.” In addition, Sotera stated that it employed adequate and effective safeguards to control EtO emissions. Moreover, Sotera and its executives vehemently denied allegations that the Company’s EtO emissions from its sterilization facilities caused cancer and other severe health issues in people living in the communities near those facilities.

On September 19, 2022, an Illinois state court jury in the first lawsuit arising from Sotera’s EtO emissions to go to trial found Sotera liable for the plaintiff’s cancer. Specifically, the jury awarded the plaintiff $363 million in damages, including $38 million in compensatory damages and $325 million in punitive damages. The jury cited Sotera’s and Sterigenics’ “willful and wanton” misconduct in not preventing toxic EtO emissions, and failing to warn about the severe health hazard posed by the Company’s Illinois facility. As a result of these disclosures, Sotera’s stock price declined by $4.90 per share, or 33.3%, from $14.73 per share on September 16, 2022, to $9.83 per share on September 19, 2022. In turn, analysts downgraded Sotera stock, causing the stock price to decline further. As of September 21, 2022, Sotera's stock traded at $7.32 per share, or more than 68% below the IPO price and nearly 73% below the SPO price.

Sotera Health Company (SHC) shareholders have legal options. If you own shares of Sotera Health Company or have incurred a recent significant loss in the stock, contact us for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Sotera Health Company settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:SHC

Release Summary
Sotera Health Company's (SHC) EtO Processing Emitted Massive Toxins and Caused Cancer in People Living in the Communities Near its Facilities
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Regencell Bioscience Holdings Limited Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

Investor Notice: Robbins LLP Informs Investors of the Globant S.A. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Globant S.A. (NYSE: GLOB) common stock between February 15, 2024 and August 14, 2025. Globant is a Luxembourg-incorporated international technology company that provides digital consulting and related services. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LL...

Investor Notice: Robbins LLP Informs Investors of the zSpace, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired zSpace, Inc. (NASDAQ: ZSPC) securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company's December 2024 initial public statement ("IPO"). zSpace purports to be a leading provider of augmented reality (AR) and virtual reality (VR) educational technology solutions.For more information, s...
Back to Newsroom